

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1647PXH

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Dec 17 The CA Lexicon available in the CAPLUS and CA files
NEWS 3 Feb 06 Engineering Information Encompass files have new names
NEWS 4 Feb 16 TOXLINE no longer being updated
NEWS 5 Apr 23 Search Derwent WPINDEX by chemical structure
NEWS 6 Apr 23 PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
NEWS 7 May 07 DGENE Reload
NEWS 8 Jun 20 Published patent applications (A1) are now in USPATFULL
NEWS 9 JUL 13 New SDI alert frequency now available in Derwent's
DWPI and DPCI
NEWS 10 Aug 23 In-process records and more frequent updates now in
MEDLINE
NEWS 11 Aug 23 PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
NEWS 12 Aug 23 Adis Newsletters (ADISNEWS) now available on STN
NEWS 13 Sep 17 IMSworld Pharmaceutical Company Directory name change
to PHARMASEARCH
NEWS 14 Oct 09 Korean abstracts now included in Derwent World Patents
Index
NEWS 15 Oct 09 Number of Derwent World Patents Index updates increased
NEWS 16 Oct 15 Calculated properties now in the REGISTRY/ZREGISTRY File
NEWS 17 Oct 22 Over 1 million reactions added to CASREACT
NEWS 18 Oct 22 DGENE GETSIM has been improved
NEWS 19 Oct 29 AAASD no longer available

NEWS EXPRESS August 15 CURRENT WINDOWS VERSION IS V6.0c,
CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001

=> FILE BIOSIS CAPLUS MEDLINE
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
1.20	1.20

FILE 'BIOSIS' ENTERED AT 12:51:27 ON 06 NOV 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'CAPLUS' ENTERED AT 12:51:27 ON 06 NOV 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001

=> E DRUG DELIVERY

E1 2 DRUFTERS/BI
E2 4336667 DRUG/BI
E3 0 --> DRUG DELIVERY/BI
E4 1 DRUG0/BI
E5 1 DRUG1/BI
E6 1 DRUG2/BI
E7 1 DRUG5/BI
E8 1 DRUG5EFFECT/BI
E9 28 DRUGA/BI
E10 5 DRUGABILITY/BI
E11 5 DRUGABLE/BI
E12 2 DRUGABUSE/BI

=> S DRUG

L1 4711359 DRUG

=> S DELIVERY

L2 325070 DELIVERY

=> S L1 AND L2

L3 132623 L1 AND L2

=> S (DRUG OR COMPOUND) (W) DELIVERY

L4 92862 (DRUG OR COMPOUND) (W) DELIVERY

=> D 1

L4 ANSWER 1 OF 92862 BIOSIS COPYRIGHT 2001 BIOSIS
AN 2001:512575 BIOSIS
DN PREV200100512575
TI Clostridial hydrolytic enzymes degrading extracellular components.
AU Matsushita, Osamu (1); Okabe, Akinobu
CS (1) Department of Microbiology, Kagawa Medical University, Takamatsu:
microbio@kms.ac.jp Japan
SO Toxicon, (November, 2001) Vol. 39, No. 11, pp. 1769-1780. print.
ISSN: 0041-0101.
DT General Review
LA English
SL English

=> S POLYSACCHARIDE POLYMER

L5 288 POLYSACCHARIDE POLYMER

=> S L4 AND L5

L6 6 L4 AND L5

=> D L6 1-6

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 2001:319658 CAPLUS
DN 134:322072
TI Encapsulation of active material within polysaccharide or polymer hydrogel
microbeads
IN Quong, Douglas
PA 3M Innovative Properties Company, USA
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 2001030145 A1 20010303 WO 2000-US27947 20001010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 1999-425636 A 19991022

RE.CNT 10

RE
(1) Anon; JP 04310233 A CAPLUS
(2) Anon; JP 04310233 A CAPLUS
(4) Kureha Chem Ind Co Ltd; JP 04310233 A 1992 CAPLUS
(5) Lee County Mosquito Control DI; WO 8912450 A 1989 CAPLUS
(6) Martinsen, A; BIOTECHNOLOGY AND BIOENGINEERING 1992, V39(2), P186 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 2000:401630 CAPLUS
DN 133:34450
TI Pharmaceutical compositions based on phospholipids and polymers
IN Leigh, Steven; Leigh, Mathew Louis Steven
PA Phares Pharmaceutical Research N.V., Neth. Antilles
SO PCT Int. Appl., 43 pp.
CODEN: PIXXD2

DT Patent
LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000033817	A1	20000615	WO 1999-GB4070	19991208
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2344520	A1	20000614	GB 1998-27006	19981208
EP 1137402	A1	20011004	EP 1999-961183	19991208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI GB 1998-27006	A	19981208		
GB 1999-25365	A	19991027		
WO 1999-GB4070	W	19991208		

RE.CNT 6

RE
(1) BASF AG; DE 19531277 A 1997 CAPLUS
(2) Ciba-Geigy; EP 0181287 A 1986 CAPLUS
(4) Nippon Oils & Fats Co; JP 06-245719 A 1994 CAPLUS
(5) Phares Pharmaceutical Research NV; WO 9858629 A 1998 CAPLUS
(6) Tanabe Seiyaku Co; JP 07-291854 A CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS
AN 2000:335277 CAPLUS
DN 133:9149
TI Polymer grafting with polysaccharide synthases for coating biomaterial surfaces
IN Deangelis, Paul L.
PA The Board of Regents of the University of Oklahoma, USA
SO PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027437	A2	20000518	WO 1999-US26501	19991110
	WO 2000027437	A3	20000720		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000016139	A5	20000529	AU 2000-16139	19991110
	EP 1129209	A2	20010905	EP 1999-958858	19991110
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
PRAI	US 1998-107929	P	19981111		
	US 1999-283402	A	19990401		
	WO 1999-US26501	W	19991110		

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1999:690936 CAPLUS

DN 131:303394

TI Orally administrable compositions comprising cation crosslinked polysaccharide and a polymer digestible in the lower gastrointestinal tract

IN Tester, Richard Frank; Karkalas, John

PA Glasgow Caledonian University, UK

SO PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953902	A1	19991028	WO 1999-GB1240	19990422
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9936182	A1	19991108	AU 1999-36182	19990422
	EP 1079810	A1	20010307	EP 1999-918147	19990422
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	GB 1998-8595	A	19980422		
	GB 1998-10375	A	19980514		
	WO 1999-GB1240	W	19990422		

RE.CNT 2

RE

- (1) Ishmael, J; International Journal of Pharmaceutics 1995, V126, P161
(2) Pharmacaps Inc; EP 0243930 A 1987 CAPLUS

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1999:565920 CAPLUS

DN 131:165296

TI Therapeutic and prophylactic uses of negatively charged substituted disaccharides in infections by Neisseria gonorrhoeae

IN Navia, Manuel A.; Quinn, Thomas C.

PA The Althexis Company, USA; Usa, Secretary Department of Health and Human Services

SO PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9943333	A1	19990902	WO 1999-US4432	19990226
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9927982	A1	19990915	AU 1999-27982	19990226
PRAI	US 1998-76314	A1	19980227		
	WO 1999-US4432	W	19990226		

RE.CNT 2

RE

- (1) Bukh Meditec; EP 0640346 A1 1988 CAPLUS
(2) Koch; US 5538954 A 1996 CAPLUS

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS

AN 1999:286211 CAPLUS

DN 130:316656

TI Osmotic drug delivery system

IN Kettelhoit, Stefan; Kanikanti, Ranga-Rao; Brendel, Erich; Weisemann, Claus; Chantraine, Ernst; Eisele, Michael; Bosche, Patrick

PA Bayer A.-G., Germany

SO Ger. Offen., 10 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 19747261	A1	19990429	DE 1997-19747261	19971025
	WO 9921535	A1	19990506	WO 1998-EP6454	19981012
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 9912278	A1	19990517	AU 1999-12278	19981012
EP	1024793	A1	20000809	EP 1998-955434	19981012
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
	US 6294201	B1	20010925	US 2000-530158	20000425
PRAI	DE 1997-19747261	A	19971025		
	WO 1998-EP6454	W	19981012		

=> D HIS

(FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001

E DRUG DELIVERY

L1 4711359 S DRUG

L2 325070 S DELIVERY

L3 132623 S L1 AND L2

L4 92862 S (DRUG OR COMPOUND) (W) DELIVERY

L5 288 S POLYSACCHARIDE POLYMER

L6 6 S L4 AND L5

=> D L6 1-6 IBIB ABS

L6 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2001:319658 CAPLUS

DOCUMENT NUMBER: 134:322072

TITLE: Encapsulation of active material within polysaccharide
or polymer hydrogel microbeads

INVENTOR(S): Quong, Douglas

PATENT ASSIGNEE(S): 3M Innovative Properties Company, USA

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001030145	A1	20010503	WO 2000-US27947	20001010

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-425636 A 19991022

AB A method of delivering active material, i.e., pheromones, mercaptan-contg. compds., herbicides, pesticides and pharmaceutical materials using microbeads comprising droplets of active material entrained in a hydrophilic matrix of polysaccharides or polymers is described. Compns. comprising the microbeads may be sprayable. The microbeads of the invention may be controllable by exposing the microbeads to high or low humidity or moisture. For example, hydrogel microbeads were prep'd. contg. 20 g pheromone Z11-C14 acetate and 800 g Na alginate in presence of 1000 mM Ca²⁺ and 2 g Igepal CO-630 surfactant.

REFERENCE COUNT: 10

REFERENCE(S): (1) Anon; JP 04310233 A CAPLUS
(2) Anon; JP 04310233 A CAPLUS
(4) Kureha Chem Ind Co Ltd; JP 04310233 A 1992 CAPLUS
(5) Lee County Mosquito Control DI; WO 8912450 A 1989 CAPLUS
(6) Martinsen, A; BIOTECHNOLOGY AND BIOENGINEERING 1992, V39(2), P186 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:401630 CAPLUS

DOCUMENT NUMBER: 133:34450

TITLE: Pharmaceutical compositions based on phospholipids and polymers

INVENTOR(S): Leigh, Steven; Leigh, Mathew Louis Steven

PATENT ASSIGNEE(S): Phares Pharmaceutical Research N.V., Neth. Antilles

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033817	A1	20000615	WO 1999-GB4070	19991208

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU,
CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,

SK, SL, TJ, TM, TH, TI, TQ, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

GB 2344520 A1 20000614 GB 1998-27006 19981208

EP 1137402 A1 20011004 EP 1999-961183 19991208

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:

GB 1998-27006 A 19981208

GB 1999-25365 A 19991027

WO 1999-GB4070 W 19991208

AB The present invention relates to the prepn. of powder or solid compns. comprising single and double chain amphiphilic lipids in assocn. with polymers which harden them so that they can be comminuted into powder or granules. The compns. can act as carriers for biol. active compds. and can be administered to living organisms. Such a compn. may comprise a biol. active compd. and monoacyl and diacyl membrane lipid in assocn. with a polymer, said compn. being a solid that when stored in a glass container remains free flowing after 3 mo at 40 °C and 75 % relative humidity. The lipids may be selected from those which have GRAS (generally regarded as safe) status, e.g. enzyme-modified lecithin, and the polymer may be selected from natural polysaccharide polymers, starches and their derivs., cellulose and its derivs. and gelatins. For example, a solid formulation was prepd. contg. flurbiprofen, VP 200 (a lipid contg. 60% by wt. of monoacyl phosphatidylcholine and 40% phosphatidylcholine), and Eudragit in a ratio of 1:10:10, resp. The compn. may be filled into hard gelatin capsules or may be compressed into tablets.

REFERENCE COUNT:

6

REFERENCE(S):

- (1) BASF AG; DE 19531277 A 1997 CAPLUS
- (2) Ciba-Geigy; EP 0181287 A 1986 CAPLUS
- (4) Nippon Oils & Fats Co; JP 06-245719 A 1994 CAPLUS
- (5) Phares Pharmaceutical Research NV; WO 9858629 A 1998 CAPLUS
- (6) Tanabe Seiyaku Co; JP 07-291854 A CAPLUS

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 2000:335277 CAPLUS

DOCUMENT NUMBER: 133:9149

TITLE: Polymer grafting with polysaccharide synthases for coating biomaterial surfaces

INVENTOR(S): Deangelis, Paul L.

PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA

SOURCE: PCT Int. Appl., 86 pp.

CODEN: PIXXD2

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027437	A2	20000518	WO 1999-US26501	19991110
WO 2000027437	A3	20000720		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000016139	A5	20000529	AU 2000-16139	19991110
EP 1129209	A2	20010905	EP 1999-958858	19991110
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, LT, LV, FI, NO
PRIORITY APPLN. INFO.:

US 1998-107929 P 19981111
US 1999-283402 A 19990401
WO 1999-US26501 W 19991110

AB The present invention relates to methodol. for polymer grafting by a polysaccharide synthase and, more particularly, polymer grafting using the hyaluronate synthase from *Pasteurella multocida*. The present invention also relates to coatings for biomaterials wherein the coatings provide protective properties to the biomaterial and/or act as a bioadhesive. Such coatings could be applied to elec. devices, sensors, catheters and any device which may be contemplated for use within a mammal. The present invention further relates to **drug delivery** matrixes which are biocompatible and may comprise combinations of a biomaterial or a bioadhesive and a medicament or a medicament-contg. liposome. The biomaterial and/or bioadhesive is a hyaluronic acid polymer produced by a hyaluronate synthase from *Pasteurella multocida*. The present invention also relates to the creation of chimeric mols. contg. hyaluronic acid or hyaluronic acid-like chains attached to various compds. and esp. carbohydrates or hydroxyl contg. substances. The present invention also relates to a chondroitin synthase from *Pasteurella multocida* which is capable of producing **polysaccharide polymers** on an acceptor or primer mol.

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:690936 CAPLUS

DOCUMENT NUMBER: 131:303394

TITLE: Orally administrable compositions comprising cation crosslinked polysaccharide and a polymer digestible in the lower gastrointestinal tract

INVENTOR(S): Tester, Richard Frank; Karkalas, John

PATENT ASSIGNEE(S): Glasgow Caledonian University, UK

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9953902	A1	19991028	WO 1999-GB1240	19990422
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9936182	A1	19991108	AU 1999-36182	19990422
EP 1079810	A1	20010307	EP 1999-918147	19990422
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			

PRIORITY APPLN. INFO.:

GB 1998-8595 A 19980422
GB 1998-10375 A 19980514
WO 1999-GB1240 W 19990422

AB Orally administrable compns. comprising cation cross-linked polysaccharides are provided. The compns. have the ability to mask the taste and delay the release of an active material included therein. A novel method for the prepn. of the compns. is also provided. The cation cross-linked polysaccharide is preferably selected from alginic acid and demethylated pectin and the compn. further comprises a digestible polymer, preferably chosen from starch, starch derivs., .alpha.-glucans, peptides and polypeptides. A dispersion of ibuprofen in 2% alginic acid soln. was extruded into soln. of 2% calcium chloride and the beads thus obtained were sped. and dried at 40.degree.. The bead contained 75% drug and 25% polysaccharides and were resistance to 0.1 M HCl and .alpha.-amylase.

REFERENCE COUNT:

REFERENCE(S): (1) Is...el, J; International Journal of Pharmaceutics
1995, V126, P161
(2) Pharmacaps Inc; EP 0243930 A 1987 CAPLUS

L6 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:565920 CAPLUS

DOCUMENT NUMBER: 131:165296

TITLE: Therapeutic and prophylactic uses of negatively
charged substituted disaccharides in infections by
Neisseria gonorrhoeae

INVENTOR(S): Navia, Manuel A.; Quinn, Thomas C.

PATENT ASSIGNEE(S): The Althexis Company, USA; Usa, Secretary Department
of Health and Human Services

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943333	A1	19990902	WO 1999-US4432	19990226
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9927982	A1	19990915	AU 1999-27982	19990226
PRIORITY APPLN. INFO.:			US 1998-76314	A1 19980227
			WO 1999-US4432	W 19990226

AB The present invention relates to the compns. and methods of using neg. charged substituted disaccharides, e.g., sucrose octasulfate, or salts thereof alone or in combination with other agents, in treating or preventing infections by N. gonorrhoeae. A compn. for inhibiting infection of a cell by N. gonorrhoeae comprises (a) a neg. charged substituted disaccharide, sufficient to inhibit the infectivity by N. gonorrhoeae, and (b) one or more of an antibacterial agent selected from the group consisting of a DNA topoisomerase inhibitor, a protein synthesis inhibitor, a membrane transport inhibitor, and an anionic sulfated polysaccharide polymer. A neg. charged substituted disaccharide can be combined with a contraceptive agent to prevent conception and to inhibit infection by N. gonorrhoeae. A dramatic and immediate inhibitory effect of K sucrose octasulfate and sucralfate on the growth of N. gonorrhoeae was obsd. in vitro with the min. inhibitory concn. (MIC) of 0.00003 mg/mL, resp.

REFERENCE COUNT: 2

REFERENCE(S): (1) Bukh Meditec; EP 0640346 A1 1988 CAPLUS
(2) Koch; US 5538954 A 1996 CAPLUS

L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:286211 CAPLUS

DOCUMENT NUMBER: 130:316656

TITLE: Osmotic drug delivery system

INVENTOR(S): Kettelhoit, Stefan; Kanikanti, Ranga-Rao; Brendel, Erich; Weisemann, Claus; Chantraine, Ernst; Eisele, Michael; Bosche, Patrick

PATENT ASSIGNEE(S): Bayer A.-G., Germany

SOURCE: Ger. Offen., 10 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

DE 19747261	A1	19990429	DE 1997-19747261	19971025
WO 9921535	A1	19990506	WO 1998-EP6454	19981012
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,				
DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,				
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,				
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,				
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,				
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9912278	A1	19990517	AU 1999-12278	19981012
EP 1024793	A1	20000809	EP 1998-955434	19981012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				
IE, SI, LT, LV, FI, RO				
US 6294201	B1	20010925	US 2000-530158	20000425
PRIORITY APPLN. INFO.: DE 1997-19747261 A 19971025				
WO 1998-EP6454 W 19981012				

AB A single-chamber osmotic **drug delivery** system comprises a tablet contg. dihydropyridine active agent 15-35, xanthan 20-50, and vinylpyrrolidone/vinyl acetate copolymer 10-30, surrounded by a semipermeable membrane contg. a pore through which the tablet contents are slowly released. Permeation of water through the membrane causes dissoln. and swelling of the **polysaccharide-polymer** mixt.; the viscosity of this soln. decreases with increasing shear stress. This allows gradual, complete release of the dihydropyridine without rupture of the membrane which would cause premature, uncontrolled drug release. Thus, tablets for treatment of hypertension and coronary artery disease were prep'd. contg. nifedipine 36.00, xanthan 50.96, vinylpyrrolidone/vinyl acetate copolymer 29.45, NaCl 28.71, NaHCO3 10.15, Na carboxymethylstarch 12.74, Aerosil 0.85, and Mg stearate 0.68 mg; the tablets were coated with a film contg. cellulose acetate 8.45 and PEG-3350 0.45 mg/tablet, in which a pore 800 .mu.m in diam. was bored.

=> D HIS

(FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001
E DRUG DELIVERY

L1 4711359 S DRUG
L2 325070 S DELIVERY
L3 132623 S L1 AND L2
L4 92862 S (DRUG OR COMPOUND) (W) DELIVERY
L5 288 S POLYSACCHARIDE POLYMER
L6 6 S L4 AND L5

=> S LUNG (W) DELIVERY
L7 159 LUNG (W) DELIVERY

=> S L7 AND L4
L8 76 L7 AND L4

=> S L5 AND L8
L9 0 L5 AND L8

=> S POLYMERIC (W) CONSTRUCT
L10 15 POLYMERIC (W) CONSTRUCT

=> S L8 AND L10
L11 0 L8 AND L10

=> S L7 AND L10
L12 0 L7 AND L10

=> S OLYSACHARIDE
L13 0 OLYSACHARIDE

=> S POLYSACCHARIDE
L14 79 POLYSACCHARIDE

=> S POLYSACCHARIDE
L15 129436 POLYSACCHARIDE

=> D HIS

(FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001
E DRUG DELIVERY

L1 4711359 S DRUG
L2 325070 S DELIVERY
L3 132623 S L1 AND L2
L4 92862 S (DRUG OR COMPOUND) (W) DELIVERY
L5 288 S POLYSACCHARIDE POLYMER
L6 6 S L4 AND L5
L7 159 S LUNG (W) DELIVERY
L8 76 S L7 AND L4
L9 0 S L5 AND L8
L10 15 S POLYMERIC (W) CONSTRUCT
L11 0 S L8 AND L10
L12 0 S L7 AND L10
L13 0 S POLYSACCHARIDE
L14 79 S POLYSACCHARIDE
L15 129436 S POLYSACCHARIDE

=> S L7 AND L15
L16 1 L7 AND L15

=> D L16 ABS IBIB

L16 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AB Methods and formulations for delivery of macromols., such as proteins,
polysaccharides, and nucleic acids, are disclosed, where the
macromol. is dissolved or dispersed in a low toxicity org. solvent which
can be aerosolized for delivery to a patient's lungs by inhalation.
Optionally, appropriate soly. enhancers are also present in the
formulations compn.

ACCESSION NUMBER: 2000:513486 CAPLUS
DOCUMENT NUMBER: 133:125304
TITLE: Nonaqueous solutions and suspensions of macromolecules
for pulmonary delivery
INVENTOR(S): Klibanov, Alexander M.
PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042993	A2	20000727	WO 2000-US957	20000114
WO 2000042993	A3	20001130		

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE

PRIORITY APPLN. INFO.: US 1999-116860 P 19990122
US 1999-443716 A 19991119

=> D HIS

(FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001

E DRUG DELIVERY

L1 4711359 S DRUG

L2 325070 S DELIVERY

L3 132623 S L1 AND L2

L4 92862 S (DRUG OR COMPOUND) (W) DELIVERY

L5 288 S POLYSACCHARIDE POLYMER

L6 6 S L4 AND L5

L7 159 S LUNG (W) DELIVERY

L8 76 S L7 AND L4

L9 0 S L5 AND L8

L10 15 S POLYMERIC (W) CONSTRUCT

L11 0 S L8 AND L10

L12 0 S L7 AND L10

L13 0 S POLYSACCHARIDE

L14 79 S POLYSACCHARIDE

L15 129436 S POLYSACCHARIDE

L16 1 S L7 AND L15

=> S L15 AND L4

L17 1641 L15 AND L4

=> S L17 AND L7

L18 1 L17 AND L7

=> D L18 ABS IBIB

L18 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS

AB Methods and formulations for delivery of macromols., such as proteins, polysaccharides, and nucleic acids, are disclosed, where the macromol. is dissolved or dispersed in a low toxicity org. solvent which can be aerosolized for delivery to a patient's lungs by inhalation. Optionally, appropriate soly. enhancers are also present in the formulations compn.

ACCESSION NUMBER: 2000:513486 CAPLUS

DOCUMENT NUMBER: 133:125304

TITLE: Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery

INVENTOR(S): Klibanov, Alexander M.

PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA

SOURCE: PCT Int. Appl., 12 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042993	A2	20000727	WO 2000-US957	20000114
WO 2000042993	A3	20001130		

W: CA, JP

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.:

US 1999-116860 P 19990122

US 1999-443716 A 19991119

=> D HIS

(FILE 'HOME' ENTERED AT 12:46:45 ON 06 NOV 2001)

FILE 'BIOSIS, CAPLUS, MEDLINE' ENTERED AT 12:51:27 ON 06 NOV 2001

E DRUG DELIVERY

L1 4711359 S DRUG

L2 325070 S DELIVERY

L3 132623 S L1 AND L2

L4 92862 S (DRUG OR COMPOUND) (W) DELIVERY

L5 288 S POLYSACCHARIDE POLYMER

L6 6 S L4 AND L5

L7 159 S LUNG (W) DEL
 L8 76 S L7 AND L4
 L9 0 S L5 AND L8
 L10 15 S POLYMERIC (W) CONSTRUCT
 L11 0 S L8 AND L10
 L12 0 S L7 AND L10
 L13 0 S POLYSACCHARIDE
 L14 79 S POLYSACCHARIDE
 L15 129436 S POLYSACCHARIDE
 L16 1 S L7 AND L15
 L17 1641 S L15 AND L4
 L18 1 S L17 AND L7

=> D L3 AND L7
 L7 IS NOT VALID HERE
 For an explanation, enter "HELP DISPLAY".

=> S L7 AND L5
 L19 0 L7 AND L5

=> S L3 AND L15
 L20 1750 L3 AND L15

=> S L4 AND L15
 L21 1641 L4 AND L15

=> S L21 AND L7
 L22 1 L21 AND L7

=> D L22 ABS IBIB

L22 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
 AB Methods and formulations for delivery of macromols., such as proteins, polysaccharides, and nucleic acids, are disclosed, where the macromol. is dissolved or dispersed in a low toxicity org. solvent which can be aerosolized for delivery to a patient's lungs by inhalation. Optionally, appropriate soly. enhancers are also present in the formulations compn.

ACCESSION NUMBER: 2000:513486 CAPLUS
 DOCUMENT NUMBER: 133:125304
 TITLE: Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
 INVENTOR(S): Klibanov, Alexander M.
 PATENT ASSIGNEE(S): Massachusetts Institute of Technology, USA
 SOURCE: PCT Int. Appl., 12 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000042993	A2	20000727	WO 2000-US957	20000114
WO 2000042993	A3	20001130		
W: CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
PRIORITY APPLN. INFO.:		US 1999-116860	P	19990122
		US 1999-443716	A	19991119